Piper Sandler Downgrades Nevro to Underweight, Lowers Price Target to $38
Piper Sandler analyst Adam Maeder downgrades Nevro (NYSE:NVRO) from Neutral to Underweight and lowers the price target from $42 to $38.
Benzinga’s Top Ratings Upgrades, Downgrades For December 12, 2022
Upgrades For Colliers International Group Inc (NASDAQ:CIGI), Goldman Sachs upgraded the previous rating of Neutral to Buy. Colliers…
Wells Fargo Downgrades Nevro to Equal-Weight, Lowers Price Target to $43
Wells Fargo analyst Larry Biegelsen downgrades Nevro (NYSE:NVRO) from Overweight to Equal-Weight and lowers the price target from $66 to $43.
Nevro Secures FDA Nod HFX iQ Spinal Cord Stimulation System For to Personalize Pain Treatment
The FDA approved Nevro Corp’s (NYSE:NVRO) Senza HFX iQ spinal cord stimulation (SCS) system. Senza HFX iQ is the first and…
Nevro Late Wednesday Announces FDA Approval Of HFX iQ Spinal Cord Stimulation System To Personalize The Treatment of Chronic Pain
Next Generation Senza® HFX iQ™ is the First and Only SCS System that Uses Artificial Intelligence to Optimize and Maintain Pain Relief Using Each Patient's Response
REDWOOD CITY, Calif., Oct. 12,
Jefferies Initiates Coverage On Nevro with Underperform Rating, Announces Price Target of $31
Jefferies analyst Matthew Taylor initiates coverage on Nevro (NYSE:NVRO) with a Underperform rating and announces Price Target of $31.
Nevro Wins Multiple Coverage Options For Spinal Cord Stimulation In Diabetic Neuropathy
Nevro Corp (NYSE:NVRO) announced positive updates to multiple spinal cord stimulation (SCS) coverage policies. Aetna’s new SCS policy explicitly covers PDN…
Morgan Stanley Maintains Equal-Weight on Nevro, Lowers Price Target to $54
Morgan Stanley analyst David Lewis maintains Nevro (NYSE:NVRO) with a Equal-Weight and lowers the price target from $55 to $54.